BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riechelmann RP, Weschenfelder RF, Costa FP, Andrade AC, Osvaldt AB, Quidute AR, Dos Santos A, Hoff AA, Gumz B, Buchpiguel C, Vilhena Pereira BS, Lourenço Junior DM, da Rocha Filho DR, Fonseca EA, Riello Mello EL, Makdissi FF, Waechter FL, Carnevale FC, Coura-Filho GB, de Paulo GA, Girotto GC, Neto JE, Glasberg J, Casali-da-Rocha JC, Rego JF, de Meirelles LR, Hajjar L, Menezes M, Bronstein MD, Sapienza MT, Fragoso MC, Pereira MA, Barros M, Forones NM, do Amaral PC, de Medeiros RS, Araujo RL, Bezerra RO, Peixoto RD, Aguiar S Jr, Ribeiro U Jr, Pfiffer T, Hoff PM, Coutinho AK. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. Ecancermedicalscience 2017;11:716. [PMID: 28194228 DOI: 10.3332/ecancer.2017.716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Spencer RMSSB, de Camargo VP, Silva MLG, Pinto FFE, Costa FD, Cequeira WS, Munhoz RR, Mello CA, Schmerling RA, Filho WJD, Coelho TM, Ambrosio AVA, Leite ETT, Hanna SA, Nakagawa SA, Baptista AM, Pinheiro RN, de Oliveira JL, de Araújo MS, de Araujo RLC, Laporte GA, de Almeida Quadros C, de Oliveira AF, Lopes A. Brazilian consensus on the diagnosis and treatment of extremities soft tissue sarcomas. J Surg Oncol 2020;121:743-58. [PMID: 31970785 DOI: 10.1002/jso.25847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
3 Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol 2019;10:645-51. [PMID: 31392045 DOI: 10.21037/jgo.2019.01.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist 2019;24:e1315-20. [PMID: 31332100 DOI: 10.1634/theoncologist.2018-0675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tanaka H, Uema D, Rego JFM, Weschenfelder RF, D'Agustini N, Filho DRR, O'Connor JM, Luca R, Nuñez JER, de Barros E Silva MJ, Riechelmann RP. Health resource utilisation by patients with neuroendocrine tumours with or without carcinoid heart disease: a multinational study. Ecancermedicalscience 2020;14:1141. [PMID: 33343700 DOI: 10.3332/ecancer.2020.1141] [Reference Citation Analysis]
7 Uema D, Alves C, Mesquita M, Nuñez JE, Siepmann T, Angel M, Rego JFM, Weschenfelder R, Rocha Filho DR, Costa FP, Barros M, O'Connor JM, Illigens BM, Riechelmann RP. Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study. J Clin Med 2019;8:E405. [PMID: 30909590 DOI: 10.3390/jcm8030405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Petersenn S, Koch CA. Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord 2017;18:373-8. [DOI: 10.1007/s11154-018-9442-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Nakaoka K, Hashimoto S, Kawabe N, Kuzuya T, Yamada S, Sawaki A, Funasaka K, Nagasaka M, Nakagawa Y, Miyahara R, Shibata T, Tsukamoto T, Hirooka Y. A rare case of pancreatic neuroendocrine neoplasm causing Cushing’s syndrome. Clin J Gastroenterol. [DOI: 10.1007/s12328-021-01563-8] [Reference Citation Analysis]
10 Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;94:102168. [PMID: 33730627 DOI: 10.1016/j.ctrv.2021.102168] [Reference Citation Analysis]
11 do Amor Divino PH, Marchetti KR, Almeida MQ, Riechelmann RP. Functional pancreatic neuroendocrine tumour causing Cushing's syndrome: the effect of chemotherapy on clinical symptoms. Ecancermedicalscience 2017;11:773. [PMID: 29104610 DOI: 10.3332/ecancer.2017.773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Alves C, Mesquita M, Silva C, Soeiro M, Hajjar L, Riechelmann RP. High tumour burden, delayed diagnosis and history of cardiovascular disease may be associated with carcinoid heart disease. Ecancermedicalscience 2018;12:879. [PMID: 30483359 DOI: 10.3332/ecancer.2018.879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]